Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eledon Pharmaceuticals (ELDN) EBT (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of EBT readings, the most recent being -$2.1 million for Q4 2017.

  • On a quarterly basis, EBT rose 43.67% to -$2.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$13.1 million, a 25.7% increase, with the full-year FY2025 number at -$45.6 million, down 27.49% from a year prior.
  • EBT hit -$2.1 million in Q4 2017 for Eledon Pharmaceuticals, up from -$3.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$883000.0 in Q2 2016 to a low of -$13.3 million in Q1 2015.
  • Median EBT over the past 5 years was -$5.7 million (2013), compared with a mean of -$6.0 million.
  • Biggest five-year swings in EBT: soared 90.14% in 2016 and later crashed 654.93% in 2017.
  • Eledon Pharmaceuticals' EBT stood at -$5.5 million in 2013, then dropped by 11.88% to -$6.2 million in 2014, then tumbled by 77.46% to -$11.0 million in 2015, then skyrocketed by 66.08% to -$3.7 million in 2016, then skyrocketed by 43.67% to -$2.1 million in 2017.
  • The last three reported values for EBT were -$2.1 million (Q4 2017), -$3.0 million (Q3 2017), and -$6.7 million (Q2 2017) per Business Quant data.